This webinar has been funded by medac GmbH.
Explore the evolving role of methotrexate (MTX) in rheumatoid arthritis (RA) care in this expert-led podcast featuring leading international rheumatologists. Topics include the benefits of subcutaneous MTX, vaccination considerations during MTX therapy and lessons from COVID-19, updates on second-line combination treatments, and the latest evidence on MTX-associated fibrotic interstitial lung disease.
Topics Covered
- 00:00: Introduction and Welcome
- 03:22: Methotrexate in Canada: RWE – CATCH
- 20:40: Vaccination on MTX therapy – What did we learn from COVID-19?
- 36:32: Update on Combination Therapy with Methotrexate in Patients with RA
- 49:33: Methotrexate and the Lung – latest evidence in fibrotic lung disease
- 01:12:31: Questions
Speakers
Carter Thorne1
Gerd R. Burmester2
Axel Finckh3
Puja Mehta 4
1. Professor in the Division of Rheumatology at the University of Toronto, and Chief Director, Division of Rheumatology, Southlake Regional Health Centre, Newmarket, Ontario, Canada.
2. Senior Professor, Department of Rheumatology and Clinical Immunology, Charité – University Hospital of Berlin, Germany.
3. Professor in the Department of Medicine; Deputy Head, Division of Rheumatology, and Lead of Clinical Research, University of Geneva (HUG), Switzerland.
4. Senior Specialist Registrar in Rheumatology and PhD Candidate (Post-COVID Interstitial Lung Disease), Respiratory Division, University College London (UCL), UK.
